Therefore, CETP has become a target for the treatment of dyslipidemia, and CETP inhibitors are expected to be a powerful class of drugs for increasing HDL and decreasing LDL levels, which should help reduce the risk of atherosclerotic CVD [4,6,7]. Here, CETP is linked to metabolic syndrome.